Wanbury is about to launch two new products, for formulation (Branded generic) div., Branded Hematinic Iron tablets WANBURY C-RED and for API (Bulk Drug) div - launching KETAMINE HYDROCHLORIDE.
Wanbury held strong equity in gynecology segment, to capitalize on the same. Wanbury is launching for iron deficiency, Iron tablets, by brand name "WANBURY C-RED". Its an iron supplement, which helps improving hemoglobin in the blood of individuals especially during pregnancy. Earlier it had well-known brand C Pink which was divested few years ago during debt settlement.
Prevalence of Anemia is very high in India-Both male & female, more than 40% of Indians are anemic.
Liposomal iron is a new & better product compared to various iron salts existing in the market, which prevents gastric irritation & constipation, ensures better absorption with quick Hb rise, besides excellent safety with tolerability with no oxidative damages.
KETAMINE HYDROCHLORIDE:
The Ketamine is developed by a unique cost competitive process & quality product by In - house R&D team in compliance with all the major pharmacopeia such as USP & EP. Ketamine has annual demand of over 200 tons for both human and veterinary market.
Ketamine is used to promote sleep before & during surgeries. Dr. injects this medicine into vein of patient in a hospital.
Wanbury is commencing supply of Ketamine during this month with export for European markets.
Shares of Wanbury Limited was last trading in BSE at Rs. 239.35 as compared to the previous close of Rs. 234.85. The total number of shares traded during the day was 15024 in over 798 trades.
The stock hit an intraday high of Rs. 253.30 and intraday low of 234.65. The net turnover during the day was Rs. 3619440.00.